CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2019; 55(02): 092-097
DOI: 10.1055/s-0039-1697239
Review Article
National Academy of Medical Sciences (India)

Small Dense Low-Density Lipoprotein: Biomarker or Potential Drug Target?

Basabdatta Samanta
1   Department of Biochemistry, Burdwan Medical College, West Bengal, India
› Author Affiliations
Further Information

Publication History

Publication Date:
02 October 2019 (online)

Abstract

Ischemic heart disease is currently an epidemic affecting individuals worldwide. Increased incidence along with earlier onset of disease has led to the constant search for biomarkers that will help in earlier identification and treatment of at risk individuals. Small dense low-density lipoprotein (sdLDL) is the atherogenic subtype of low-density lipoprotein (LDL). It is smaller in size and higher in density in comparison to other LDL subtypes. Higher levels of sdLDL have beenfound to be associated with increased incidence of ischemic heart disease and adverse outcomes. Properties including decreased resistance to oxidative stress and prolonged residence time in the circulation account for its increased atherogenic potential. Hence intervention approaches targeting sdLDL directly in at risk individuals may be beneficial.

Genetic, lifestyle, and environmental factors affect sdLDL levels.But the main determining factor is the level of triglycerides (TGs). Higher TG levels are associated with higher levels of very low density lipoprotein (VLDL) 1 and sdLDL. Various drugs have been used for targeting sdLDL with varying outcomes; drugs tried out include statins, fibrates, niacin, cholesterol ester transfer protein inhibitors and sodium-glucose co-transporter-2 inhibitors. Future prospects include modification of enzymes involved in fatty acid and TG synthesis, for example, lipoprotein lipase and acyl CoA carboxylase. However, further research is still necessary to draw clear guidelines for sdLDL reduction therapy in coronary artery disease treatment and prevention.

 
  • 1 Mozaffarian D, Benjamin EJ. Go AS et al. Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 2016; 133 (04) 447-454
  • 2 Krishnan MN. Coronary heart disease and risk factors in India—on the brink of an epidemic?. Indian Heart J 2012; 64 (04) 364-367
  • 3 Gupta R, Mohan I, Narula J. Trends in coronary heart disease epidemiology in India. Ann Glob Health 2016; 82 (02) 307-315
  • 4 Gupta R, Misra A, Vikram NK. et al. Younger age of escalation of cardiovascular risk factors in Asian Indian subjects. BMC Cardiovasc Disord 2009; 9: 28
  • 5 Prabhakaran D, Jeemon P, Roy A. Cardiovascular diseases in India: current epidemiology and future directions. Circulation 2016; 133 (16) 1605-1620
  • 6 Nishikura T, Koba S, Yokota Y. et al. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. J Atheroscler Thromb 2014; 21 (08) 755-767
  • 7 Yusuf S, Hawken S, Ounpuu S. et al. INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study)case-control study. Lancet 2004; 364 9438 937-952
  • 8 Werner RM, Pearson TA. LDL-cholesterol. a risk factor for coronary artery disease—from epidemiology to clinical trials. Can J Cardiol 1998; 14 Suppl B 3B-10B
  • 9 Baigent C, Keech A, Kearney PM. et al. Cholesterol Treatment Trialists'(CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366 9493 1267-1278
  • 10 Afilalo J, Majdan AA, Eisenberg MJ. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease. a comparative meta-analysis of randomised controlled trials. Heart 2007; 93 (08) 914-921
  • 11 Khalil R, Al-Azab D, Akl OA. Is sdLDL a valuable screening tool for cardiovascular disease in patients with metabolic syndrome. Alex J Med 2017; 53 (04) 299-305
  • 12 Griffin BA, Freeman DJ, Tait GW. et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis 1994; 106 (02) 241-253
  • 13 Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low-density lipoprotein as biomarker for atherosclerotic diseases. Oxid Med Cell Longev 2017 2017; 1273042
  • 14 Krauss RM, Blanche PJ. Detection and quantitation of LDL subfractions. Curr Opin Lipidol 1992; 3 (06) 377-383
  • 15 Austin MA, Brunzell JD, Fitch WL, Krauss RM. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Arterioscler Dallas Tex 1990; 10 (04) 520-530
  • 16 Zeljkovic A, Vekic J, Spasojevic-Kalimanovska V. et al. LDL and HDL subclasses in acute ischemic stroke: prediction of risk and short-term mortality. Atherosclerosis 2010; 210 (02) 548-554
  • 17 Ai M, Otokozawa S, Asztalos BF. et al. Small dense LDL cholesterol and coronary heart disease. results from the Framingham Offspring Study. Clin Chem 2010; 56 (06) 967-976
  • 18 Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990; 82 (02) 495-506
  • 19 National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106 (25) 3143-3421
  • 20 Packard CJ. Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein. Biochem Soc Trans 2003; 31: 1066-1069
  • 21 St-Pierre AC, Cantin B, Dagenais GR. et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25 (03) 553-559
  • 22 Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res 2002; 43 (09) 1363-1379
  • 23 Keech A, Simes RJ, Barter P. et al. FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366 (9500) 1849-1861
  • 24 Bezafibrate IPB, Bezafibrate Infarction Prevention (BIP) study. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102 (01) 21-27
  • 25 Manninen V, Tenkanen L, Koskinen P. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85 (01) 37-45
  • 26 Perkins Jr WJ. Combination lipid therapy in Type 2 diabetes. N Engl J Med 2010; 363: 692-695
  • 27 Xiao C, Dash S, Morgantini C, Hegele RA, Lewis GF. Pharmacological targeting of the atherogenic dyslipidemia complex. the next frontier in CVD prevention beyond lowering LDL cholesterol. Diabetes 2016; 65 (07) 1767-1778
  • 28 Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210 (02) 353-361
  • 29 Boden WE, Probstfield JL, Anderson T. et al. AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365 (24) 2255-2267
  • 30 Bloomfield D, Carlson GL, Sapre A. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009; 157 (02) 352-360
  • 31 Teramoto T, Numaguchi H, Shirakawa M. et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in Japanese patients with dyslipidemia. J Am Coll Cardiol 2012; 59 (Suppl. 13) E1689
  • 32 Nishikido T, Oyama J, Keida T, Ohira H, Node K. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL. the Standard versus high-dose therApy with Rosuvastatin for lipi D lowering (SARD) trial. J Cardiol 2016; 67 (04) 340-346
  • 33 Fukushima Y, Hirayama S, Ueno T. et al. Small dense LDL cholesterol is a robust therapeutic marker of statin treatment in patients with acute coronary syndrome and metabolic syndrome. Clin Chim Acta 2011; 412 (15-16) 1423-1427
  • 34 Choi CU, Seo HS, Lee EM. et al. Statins do not decrease small, dense low-density lipoprotein. Tex Heart Inst J 2010; 37 (04) 421-428
  • 35 Hayashi T, Fukui T, Nakanishi N. et al. Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin. Cardiovasc Diabetol 2017; 16 (01) 8
  • 36 Gaudet D, Méthot J, Déry S. et al Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency. an open-label trial. Gene Ther 2013; 20 (04) 361-369
  • 37 Graham MJ, Lee RG, Bell TA. III. et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res 2013; 112 (11) 1479-1490
  • 38 Wang Y, Gusarova V, Banfi S, Gromada J, Cohen JC, Hobbs HH. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J Lipid Res 2015; 56 (07) 1296-1307
  • 39 Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab 2009; 297 (01) E10-E18
  • 40 Griffith DA, Kung DW, Esler WP. et al. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J Med Chem 2014; 57 (24) 10512-10526
  • 41 Pinkosky SL, Filippov S, Srivastava RAK. et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res 2013; 54 (01) 134-151
  • 42 Ballantyne CM, Davidson MH, Macdougall DE. et al. Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia. results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol 2013; 62 (13) 1154-1162
  • 43 Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS. Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 2000; 85 (03) 977-982
  • 44 Siri-Tarino PW, Woods AC, Bray GA, Krauss RM. Reversal of small, dense LDL subclass phenotype by weight loss is associated with impaired fat oxidation. Obesity (Silver Spring) 2011; 19 (01) 61-68
  • 45 Siri-Tarino PW, Williams PT, Fernstrom HS, Rawlings RS, Krauss RM. Reversal of small, dense LDL subclass phenotype by normalization of adiposity. Obesity (Silver Spring) 2009; 17 (09) 1768-1775